Modafinil (Italian Wikipedia)

Analysis of information sources in references of the Wikipedia article "Modafinil" in Italian language version.

refsWebsite

Global rank Italian rank

28doi.org

2^nd place

7^th place

28nih.gov

4^th place

9^th place

15oadoi.org

799^th place

22^nd place

7web.archive.org

1^st place

7archive.is

87^th place

low place

4archive.org

6^th place

8^th place

3fda.gov

447^th place

644^th place

2bmj.com

1,226^th place

928^th place

2europa.eu

68^th place

57^th place

1provigil.com

low place

1psychiatrist.com

low place

1worldcat.org

5^th place

26^th place

1unibo.it

4,963^rd place

325^th place

1lww.com

2,769^th place

2,222^nd place

1psychiatryonline.org

4,032^nd place

3,374^th place

1nida

low place

1nytimes.com

7^th place

19^th place

archive.is

(EN) P. Jenner, B.-Y. Zeng, L.A. Smith, R.K.B. Pearce, B. Tel, L. Chancharme e G. Moachon, Antiparkinsonian and neuroprotective effects of modafinil in the mptp-treated common marmoset (abstract), vol. 133, Springer-Verlag, luglio 2000, pp. 178-188, DOI:10.1007/s002210000370, ISSN Print ISSN 0014-4819; Online ISSN 1432-1106 (WC · ACNP). URL consultato il 17 ottobre 2022 (archiviato dall'url originale l'11 gennaio 2013).
(EN) Menza MA, Kaufman KR e Castellanos A., Modafinil augmentation of antidepressant treatment in depression, in J Clin Psychiatry, vol. 61, n. 11, PubMed, 2000, pp. 378–381, PMID 10847314. URL consultato il 17 ottobre 2022 (archiviato dall'url originale il 31 luglio 2013).
(EN) DeBattista C, Lembke A, Solvason HB, Ghebremichael R e Poirier J., A prospective trial of modafinil as an adjunctive treatment of major depression (abstract), in J Clin Psychopharmacol, vol. 24, n. 1, 2004, pp. 87–90, DOI:10.1097/01.jcp.0000104910.75206.b9. URL consultato il 17 ottobre 2022 (archiviato dall'url originale il 31 luglio 2013).
(EN) J. R. MacDonald, PhD, J. D. Hill, MSc e M. A. Tarnopolsky, MD PhD, Modafinil reduces excessive somnolence and enhances mood in patients with myotonic dystrophy (abstract), in Neurology, vol. 59, 20 agosto 2002, pp. 1876–1880, PMID 12499477. URL consultato il 17 ottobre 2022 (archiviato dall'url originale il 18 gennaio 2013).
(EN) Webster L, Andrews M e Stoddard G., Modafinil treatment of opioid-induced sedation (abstract), in Pain Med, vol. 4, n. 2, PubMed, giugno 2003, pp. 135–140, DOI:10.1046/j.1526-4637.2003.03014.x. URL consultato il 17 ottobre 2022 (archiviato dall'url originale il 31 luglio 2013).
(EN) Hurst DL e Lajara-Nanson W., Use of modafinil in cerebral palsy (abstract), in J Child Neurology, vol. 17, n. 3, marzo 2002, pp. 169–172, DOI:10.1177/088307380201700303, PMID 12026230. URL consultato il 17 ottobre 2022 (archiviato dall'url originale il 31 luglio 2013).
(EN) Nieves AV e Lang AE, Treatment of excessive daytime sleepiness in patients with Parkinson’s disease with modafinil (abstract), in Clin. Neuropharmacol., vol. 25, n. 2, marzo 2002, pp. 111–114, DOI:10.1097/00002826-200203000-00010. URL consultato il 17 ottobre 2022 (archiviato dall'url originale il 31 luglio 2013).

archive.org

Biederman J, Pliszka SR, Modafinil improves symptoms of attention-deficit/hyperactivity disorder across subtypes in children and adolescents, in J. Pediatr., vol. 152, n. 3, marzo 2008, pp. 394–9, DOI:10.1016/j.jpeds.2007.07.052, PMID 18280848.
Baranski JV, Pigeau R, Dinich P, Jacobs I, Effects of modafinil on cognitive and meta-cognitive performance, in Hum Psychopharmacol, vol. 19, n. 5, 2004, pp. 323–32, DOI:10.1002/hup.596, PMID 15252824.
Randall DC, Shneerson JM, File SE, Cognitive effects of modafinil in student volunteers may depend on IQ, in Pharmacol. Biochem. Behav., vol. 82, n. 1, 2005, pp. 133–9, DOI:10.1016/j.pbb.2005.07.019, PMID 16140369.
Lindsay SE, Gudelsky GA, Heaton PC, Use of modafinil for the treatment of attention deficit/hyperactivity disorder, in Ann Pharmacother, vol. 40, n. 10, ottobre 2006, pp. 1829–33, DOI:10.1345/aph.1H024, PMID 16954326.

bmj.com

jnnp.bmj.com

Rammohan KW, Rosenberg JH, Lynn DJ, Blumenfeld AM, Pollak CP, Nagaraja HN, Efficacy and safety of modafinil (Provigil) for the treatment of fatigue in multiple sclerosis: a two centre phase 2 study, in J. Neurol. Neurosurg. Psychiatr., vol. 72, n. 2, febbraio 2002, pp. 179–83, PMC 1737733, PMID 11796766.
K W Rammohan, Efficacy and safety of modafinil (Provigil) for the treatment of fatigue in multiple sclerosis: a two centre phase 2 study, in Journal of Neurology Neurosurgery and Psychiatry, vol. 72, n. 2, 2002, pp. 179–183, DOI:10.1136/jnnp.72.2.179, PMID 11796766.

doi.org

dx.doi.org

Ishizuka T, Murakami M, Yamatodani A, Involvement of central histaminergic systems in modafinil-induced but not methylphenidate-induced increases in locomotor activity in rats, in Eur. J. Pharmacol., vol. 578, n. 2-3, gennaio 2008, pp. 209–15, DOI:10.1016/j.ejphar.2007.09.009, PMID 17920581.
Biederman J, Pliszka SR, Modafinil improves symptoms of attention-deficit/hyperactivity disorder across subtypes in children and adolescents, in J. Pediatr., vol. 152, n. 3, marzo 2008, pp. 394–9, DOI:10.1016/j.jpeds.2007.07.052, PMID 18280848.
Fava M, Thase ME, DeBattista C, Doghramji K, Arora S, Hughes RJ, Modafinil augmentation of selective serotonin reuptake inhibitor therapy in MDD partial responders with persistent fatigue and sleepiness, in Ann Clin Psychiatry, vol. 19, n. 3, 2007, pp. 153–9, DOI:10.1080/10401230701464858, PMID 17729016.
Dackis CA, Kampman KM, Lynch KG, Pettinati HM, O'Brien CP, A double-blind, placebo-controlled trial of modafinil for cocaine dependence, in Neuropsychopharmacology, vol. 30, n. 1, gennaio 2005, pp. 205–11, DOI:10.1038/sj.npp.1300600, PMID 15525998.
Turner DC, Clark L, Pomarol-Clotet E, McKenna P, Robbins TW, Sahakian BJ, Modafinil improves cognition and attentional set shifting in patients with chronic schizophrenia, in Neuropsychopharmacology, vol. 29, n. 7, luglio 2004, pp. 1363–73, DOI:10.1038/sj.npp.1300457, PMID 15085092.
Eduardo Lopes, Danielle Pereira e Nilce Sanny Costa da Silva Behrens, Cataplexy as a side effect of modafinil in a patient without narcolepsy, in Sleep Science, vol. 7, n. 1, 2014-3, pp. 47–49, DOI:10.1016/j.slsci.2014.07.015. URL consultato il 21 marzo 2019.
{ Turner DC, Robbins TW, Clark L, Aron AR, Dowson J, Sahakian BJ, Cognitive enhancing effects of modafinil in healthy volunteers, in Psychopharmacology (Berl.), vol. 165, n. 3, 2003, pp. 260–9, DOI:10.1007/s00213-002-1250-8, PMID 12417966.
Randall DC, Viswanath A, Bharania P, Elsabagh SM, Hartley DE, Shneerson JM, File SE, Does modafinil enhance cognitive performance in young volunteers who are not sleep-deprived?, in J Clin Psychopharmacol, vol. 25, n. 2, 2005, pp. 175–9, DOI:10.1097/01.jcp.0000155816.21467.25, PMID 15738750.
Baranski JV, Pigeau R, Dinich P, Jacobs I, Effects of modafinil on cognitive and meta-cognitive performance, in Hum Psychopharmacol, vol. 19, n. 5, 2004, pp. 323–32, DOI:10.1002/hup.596, PMID 15252824.
Müller U, Steffenhagen N, Regenthal R, Bublak P, Effects of modafinil on working memory processes in humans, in Psychopharmacology (Berl.), vol. 177, n. 1-2, 2004, pp. 161–9, DOI:10.1007/s00213-004-1926-3, PMID 15221200.
Randall DC, Shneerson JM, File SE, Cognitive effects of modafinil in student volunteers may depend on IQ, in Pharmacol. Biochem. Behav., vol. 82, n. 1, 2005, pp. 133–9, DOI:10.1016/j.pbb.2005.07.019, PMID 16140369.
(EN) P. Jenner, B.-Y. Zeng, L.A. Smith, R.K.B. Pearce, B. Tel, L. Chancharme e G. Moachon, Antiparkinsonian and neuroprotective effects of modafinil in the mptp-treated common marmoset (abstract), vol. 133, Springer-Verlag, luglio 2000, pp. 178-188, DOI:10.1007/s002210000370, ISSN Print ISSN 0014-4819; Online ISSN 1432-1106 (WC · ACNP). URL consultato il 17 ottobre 2022 (archiviato dall'url originale l'11 gennaio 2013).
(EN) Ira Jacobs e Douglas G. Bell, Effects of Acute Modafinil Ingestion on Exercise Time to Exhaustion, in Medicine & Science in Sports & Exercise, vol. 36, n. 6, 2004-06, pp. 1078, DOI:10.1249/01.MSS.0000128146.12004.4F. URL consultato il 26 febbraio 2023.
K W Rammohan, Efficacy and safety of modafinil (Provigil) for the treatment of fatigue in multiple sclerosis: a two centre phase 2 study, in Journal of Neurology Neurosurgery and Psychiatry, vol. 72, n. 2, 2002, pp. 179–183, DOI:10.1136/jnnp.72.2.179, PMID 11796766.
Lindsay SE, Gudelsky GA, Heaton PC, Use of modafinil for the treatment of attention deficit/hyperactivity disorder, in Ann Pharmacother, vol. 40, n. 10, ottobre 2006, pp. 1829–33, DOI:10.1345/aph.1H024, PMID 16954326.
Glen L. Xiong, M.D., Eric J. Christopher, M.D., and Jason Goebel, M.D., Modafinil as an Alternative to Methylphenidate as Augmentation for Depression Treatment, in Psychosomatics, vol. 46, Academy of Psychosomatic Physician, 2005, pp. 578–579, DOI:10.1176/appi.psy.46.6.578, PMID 16288139.
«Case report: Modafinil 200 mg daily replacing Methylphenidate 5 mg b.i.d in 78 year old cardiac patient»
(EN) DeBattista C, Lembke A, Solvason HB, Ghebremichael R e Poirier J., A prospective trial of modafinil as an adjunctive treatment of major depression (abstract), in J Clin Psychopharmacol, vol. 24, n. 1, 2004, pp. 87–90, DOI:10.1097/01.jcp.0000104910.75206.b9. URL consultato il 17 ottobre 2022 (archiviato dall'url originale il 31 luglio 2013).
(EN) Webster L, Andrews M e Stoddard G., Modafinil treatment of opioid-induced sedation (abstract), in Pain Med, vol. 4, n. 2, PubMed, giugno 2003, pp. 135–140, DOI:10.1046/j.1526-4637.2003.03014.x. URL consultato il 17 ottobre 2022 (archiviato dall'url originale il 31 luglio 2013).
(EN) Hurst DL e Lajara-Nanson W., Use of modafinil in cerebral palsy (abstract), in J Child Neurology, vol. 17, n. 3, marzo 2002, pp. 169–172, DOI:10.1177/088307380201700303, PMID 12026230. URL consultato il 17 ottobre 2022 (archiviato dall'url originale il 31 luglio 2013).
(EN) Nieves AV e Lang AE, Treatment of excessive daytime sleepiness in patients with Parkinson’s disease with modafinil (abstract), in Clin. Neuropharmacol., vol. 25, n. 2, marzo 2002, pp. 111–114, DOI:10.1097/00002826-200203000-00010. URL consultato il 17 ottobre 2022 (archiviato dall'url originale il 31 luglio 2013).
Hart CL, Haney M, Vosburg SK, Comer SD, Gunderson E, Foltin RW, Modafinil attenuates disruptions in cognitive performance during simulated night-shift work, in Neuropsychopharmacology, vol. 31, n. 7, luglio 2006, pp. 1526–36, DOI:10.1038/sj.npp.1300991, PMID 16395298.
Dackis CA, Kampman KM, Lynch KG, Pettinati HM, O'Brien CP, A double-blind, placebo-controlled trial of modafinil for cocaine dependence, in Neuropsychopharmacology, vol. 30, n. 1, 2005, pp. 205–11, DOI:10.1038/sj.npp.1300600, PMID 15525998.
Umanoff DF, Trial of modafinil for cocaine dependence, in Neuropsychopharmacology, vol. 30, n. 12, 2005, pp. 2298; author reply 2299–300, DOI:10.1038/sj.npp.1300866, PMID 16294193.
Dackis CA, Kampman KM, Lynch KG, Pettinati HM, O'Brien CP, Reply: Do Self-Reports Reliably Assess Abstinence in Cocaine-Dependent Patients?, in Neuropsychopharmacology, vol. 30, n. 12, 2005, pp. 2299–300, DOI:10.1038/sj.npp.1300867.
David Henderson, Modafinil-Associated Weight Loss in a Clozapine-Treated Schizoaffective Disorder Patient, in Annals of Clinical Psychiatry;, vol. 17, n. 2, aprile–giugno 2005, pp. 95–97, DOI:10.1080/10401230590932407.
Vaishnavi S, Gadde K, Alamy S, Zhang W, Connor K, Davidson JR, Modafinil for atypical depression: effects of open-label and double-blind discontinuation treatment, in J Clin Psychopharmacol, vol. 26, n. 4, agosto 2006, pp. 373–8, DOI:10.1097/01.jcp.0000227700.263.75.39, PMID 16855454.
Makris AP, Rush CR, Frederich RC, Kelly TH, Wake-promoting agents with different mechanisms of action: comparison of effects of modafinil and amphetamine on food intake and cardiovascular activity, in Appetite, vol. 42, n. 2, aprile 2004, pp. 185–95, DOI:10.1016/j.appet.2003.11.003, PMID 15010183.
Bonaventure P, Letavic M, Dugovic C, et al, Histamine H3 receptor antagonists: from target identification to drug leads, in Biochem. Pharmacol., vol. 73, n. 8, aprile 2007, pp. 1084–96, DOI:10.1016/j.bcp.2006.10.031, PMID 17129577.

europa.eu

eur-lex.europa.eu

fda.gov

U.S. Food and Drug Administration. Prescription Drug Marketing Act of 1987 (PDMA), PL 100-293. Link.
Psychopharmacologic Drugs Advisory Committee (transcript), su fda.gov, FDA, 23 marzo 2006.
Modafinil (CEP-1538) Tablets Supplemental NDA 20-717/S-019 ADHD Indication Briefing Document for Psychopharmacologic Drugs Advisory Committee Meeting (PDF), su fda.gov, FDA, 23 marzo 2006. URL consultato il 21 luglio 2007.

lww.com

journals.lww.com

(EN) Ira Jacobs e Douglas G. Bell, Effects of Acute Modafinil Ingestion on Exercise Time to Exhaustion, in Medicine & Science in Sports & Exercise, vol. 36, n. 6, 2004-06, pp. 1078, DOI:10.1249/01.MSS.0000128146.12004.4F. URL consultato il 26 febbraio 2023.

nida

National Institute on Drugs Abuse, Report of hearing in the Senate of United States in 2011 in 2019 (the last one the spokeswomen for NIDA was her director Dr. Nora Volokov, in NATIONAL INSTITUTE on DRUG ABUSE wed site at http://nida/govhttps://archives.drugabuse.gov/testimonies/2014/americas-addiction-to-opioids-heroin-prescription-drug-abuse.

nih.gov

ncbi.nlm.nih.gov

Ishizuka T, Murakami M, Yamatodani A, Involvement of central histaminergic systems in modafinil-induced but not methylphenidate-induced increases in locomotor activity in rats, in Eur. J. Pharmacol., vol. 578, n. 2-3, gennaio 2008, pp. 209–15, DOI:10.1016/j.ejphar.2007.09.009, PMID 17920581.
Engber TM, Koury EJ, Dennis SA, Miller MS, Contreras PC, Bhat RV, Differential patterns of regional c-Fos induction in the rat brain by amphetamine and the novel wakefulness-promoting agent modafinil, in Neurosci. Lett., vol. 241, n. 2-3, gennaio 1998, pp. 95–8, PMID 9507929.
Biederman J, Pliszka SR, Modafinil improves symptoms of attention-deficit/hyperactivity disorder across subtypes in children and adolescents, in J. Pediatr., vol. 152, n. 3, marzo 2008, pp. 394–9, DOI:10.1016/j.jpeds.2007.07.052, PMID 18280848.
Fava M, Thase ME, DeBattista C, Doghramji K, Arora S, Hughes RJ, Modafinil augmentation of selective serotonin reuptake inhibitor therapy in MDD partial responders with persistent fatigue and sleepiness, in Ann Clin Psychiatry, vol. 19, n. 3, 2007, pp. 153–9, DOI:10.1080/10401230701464858, PMID 17729016.
Dackis CA, Kampman KM, Lynch KG, Pettinati HM, O'Brien CP, A double-blind, placebo-controlled trial of modafinil for cocaine dependence, in Neuropsychopharmacology, vol. 30, n. 1, gennaio 2005, pp. 205–11, DOI:10.1038/sj.npp.1300600, PMID 15525998.
van Vliet SA, Vanwersch RA, Jongsma MJ, van der Gugten J, Olivier B, Philippens IH, Neuroprotective effects of modafinil in a marmoset Parkinson model: behavioral and neurochemical aspects, in Behav Pharmacol, vol. 17, n. 5-6, settembre 2006, pp. 453–62, PMID 16940766. URL consultato il 1º ottobre 2008 (archiviato dall'url originale il 26 febbraio 2012).
Turner DC, Clark L, Pomarol-Clotet E, McKenna P, Robbins TW, Sahakian BJ, Modafinil improves cognition and attentional set shifting in patients with chronic schizophrenia, in Neuropsychopharmacology, vol. 29, n. 7, luglio 2004, pp. 1363–73, DOI:10.1038/sj.npp.1300457, PMID 15085092.
Rammohan KW, Rosenberg JH, Lynn DJ, Blumenfeld AM, Pollak CP, Nagaraja HN, Efficacy and safety of modafinil (Provigil) for the treatment of fatigue in multiple sclerosis: a two centre phase 2 study, in J. Neurol. Neurosurg. Psychiatr., vol. 72, n. 2, febbraio 2002, pp. 179–83, PMC 1737733, PMID 11796766.
Rabkin JG, McElhiney MC, Rabkin R, Ferrando SJ, Modafinil treatment for fatigue in HIV+ patients: a pilot study, in J Clin Psychiatry, vol. 65, n. 12, dicembre 2004, pp. 1688–95, PMID 15641875.
Eduardo Lopes, Danielle Pereira e Nilce Sanny Costa da Silva Behrens, Cataplexy as a side effect of modafinil in a patient without narcolepsy, in Sleep Science, vol. 7, n. 1, 2014-3, pp. 47–49, DOI:10.1016/j.slsci.2014.07.015. URL consultato il 21 marzo 2019.
{ Turner DC, Robbins TW, Clark L, Aron AR, Dowson J, Sahakian BJ, Cognitive enhancing effects of modafinil in healthy volunteers, in Psychopharmacology (Berl.), vol. 165, n. 3, 2003, pp. 260–9, DOI:10.1007/s00213-002-1250-8, PMID 12417966.
Randall DC, Viswanath A, Bharania P, Elsabagh SM, Hartley DE, Shneerson JM, File SE, Does modafinil enhance cognitive performance in young volunteers who are not sleep-deprived?, in J Clin Psychopharmacol, vol. 25, n. 2, 2005, pp. 175–9, DOI:10.1097/01.jcp.0000155816.21467.25, PMID 15738750.
Baranski JV, Pigeau R, Dinich P, Jacobs I, Effects of modafinil on cognitive and meta-cognitive performance, in Hum Psychopharmacol, vol. 19, n. 5, 2004, pp. 323–32, DOI:10.1002/hup.596, PMID 15252824.
Müller U, Steffenhagen N, Regenthal R, Bublak P, Effects of modafinil on working memory processes in humans, in Psychopharmacology (Berl.), vol. 177, n. 1-2, 2004, pp. 161–9, DOI:10.1007/s00213-004-1926-3, PMID 15221200.
Randall DC, Shneerson JM, File SE, Cognitive effects of modafinil in student volunteers may depend on IQ, in Pharmacol. Biochem. Behav., vol. 82, n. 1, 2005, pp. 133–9, DOI:10.1016/j.pbb.2005.07.019, PMID 16140369.
K W Rammohan, Efficacy and safety of modafinil (Provigil) for the treatment of fatigue in multiple sclerosis: a two centre phase 2 study, in Journal of Neurology Neurosurgery and Psychiatry, vol. 72, n. 2, 2002, pp. 179–183, DOI:10.1136/jnnp.72.2.179, PMID 11796766.
Lindsay SE, Gudelsky GA, Heaton PC, Use of modafinil for the treatment of attention deficit/hyperactivity disorder, in Ann Pharmacother, vol. 40, n. 10, ottobre 2006, pp. 1829–33, DOI:10.1345/aph.1H024, PMID 16954326.
Glen L. Xiong, M.D., Eric J. Christopher, M.D., and Jason Goebel, M.D., Modafinil as an Alternative to Methylphenidate as Augmentation for Depression Treatment, in Psychosomatics, vol. 46, Academy of Psychosomatic Physician, 2005, pp. 578–579, DOI:10.1176/appi.psy.46.6.578, PMID 16288139.
«Case report: Modafinil 200 mg daily replacing Methylphenidate 5 mg b.i.d in 78 year old cardiac patient»
(EN) Menza MA, Kaufman KR e Castellanos A., Modafinil augmentation of antidepressant treatment in depression, in J Clin Psychiatry, vol. 61, n. 11, PubMed, 2000, pp. 378–381, PMID 10847314. URL consultato il 17 ottobre 2022 (archiviato dall'url originale il 31 luglio 2013).
(EN) J. R. MacDonald, PhD, J. D. Hill, MSc e M. A. Tarnopolsky, MD PhD, Modafinil reduces excessive somnolence and enhances mood in patients with myotonic dystrophy (abstract), in Neurology, vol. 59, 20 agosto 2002, pp. 1876–1880, PMID 12499477. URL consultato il 17 ottobre 2022 (archiviato dall'url originale il 18 gennaio 2013).
(EN) Hurst DL e Lajara-Nanson W., Use of modafinil in cerebral palsy (abstract), in J Child Neurology, vol. 17, n. 3, marzo 2002, pp. 169–172, DOI:10.1177/088307380201700303, PMID 12026230. URL consultato il 17 ottobre 2022 (archiviato dall'url originale il 31 luglio 2013).
Hart CL, Haney M, Vosburg SK, Comer SD, Gunderson E, Foltin RW, Modafinil attenuates disruptions in cognitive performance during simulated night-shift work, in Neuropsychopharmacology, vol. 31, n. 7, luglio 2006, pp. 1526–36, DOI:10.1038/sj.npp.1300991, PMID 16395298.
Dackis CA, Kampman KM, Lynch KG, Pettinati HM, O'Brien CP, A double-blind, placebo-controlled trial of modafinil for cocaine dependence, in Neuropsychopharmacology, vol. 30, n. 1, 2005, pp. 205–11, DOI:10.1038/sj.npp.1300600, PMID 15525998.
Umanoff DF, Trial of modafinil for cocaine dependence, in Neuropsychopharmacology, vol. 30, n. 12, 2005, pp. 2298; author reply 2299–300, DOI:10.1038/sj.npp.1300866, PMID 16294193.
Vaishnavi S, Gadde K, Alamy S, Zhang W, Connor K, Davidson JR, Modafinil for atypical depression: effects of open-label and double-blind discontinuation treatment, in J Clin Psychopharmacol, vol. 26, n. 4, agosto 2006, pp. 373–8, DOI:10.1097/01.jcp.0000227700.263.75.39, PMID 16855454.
Thase ME, Fava M, DeBattista C, Arora S, Hughes RJ, Modafinil augmentation of SSRI therapy in patients with major depressive disorder and excessive sleepiness and fatigue: a 12-week, open-label, extension study, in CNS Spectr, vol. 11, n. 2, febbraio 2006, pp. 93–102, PMID 16520686.
Makris AP, Rush CR, Frederich RC, Kelly TH, Wake-promoting agents with different mechanisms of action: comparison of effects of modafinil and amphetamine on food intake and cardiovascular activity, in Appetite, vol. 42, n. 2, aprile 2004, pp. 185–95, DOI:10.1016/j.appet.2003.11.003, PMID 15010183.
Bonaventure P, Letavic M, Dugovic C, et al, Histamine H3 receptor antagonists: from target identification to drug leads, in Biochem. Pharmacol., vol. 73, n. 8, aprile 2007, pp. 1084–96, DOI:10.1016/j.bcp.2006.10.031, PMID 17129577.

nytimes.com

nytimes.com, https://www.nytimes.com/2019/05/15/arts/design/met-museum-sackler-opioids.html Titolo mancante per url url (aiuto).

oadoi.org

Ishizuka T, Murakami M, Yamatodani A, Involvement of central histaminergic systems in modafinil-induced but not methylphenidate-induced increases in locomotor activity in rats, in Eur. J. Pharmacol., vol. 578, n. 2-3, gennaio 2008, pp. 209–15, DOI:10.1016/j.ejphar.2007.09.009, PMID 17920581.
Fava M, Thase ME, DeBattista C, Doghramji K, Arora S, Hughes RJ, Modafinil augmentation of selective serotonin reuptake inhibitor therapy in MDD partial responders with persistent fatigue and sleepiness, in Ann Clin Psychiatry, vol. 19, n. 3, 2007, pp. 153–9, DOI:10.1080/10401230701464858, PMID 17729016.
Dackis CA, Kampman KM, Lynch KG, Pettinati HM, O'Brien CP, A double-blind, placebo-controlled trial of modafinil for cocaine dependence, in Neuropsychopharmacology, vol. 30, n. 1, gennaio 2005, pp. 205–11, DOI:10.1038/sj.npp.1300600, PMID 15525998.
Turner DC, Clark L, Pomarol-Clotet E, McKenna P, Robbins TW, Sahakian BJ, Modafinil improves cognition and attentional set shifting in patients with chronic schizophrenia, in Neuropsychopharmacology, vol. 29, n. 7, luglio 2004, pp. 1363–73, DOI:10.1038/sj.npp.1300457, PMID 15085092.
{ Turner DC, Robbins TW, Clark L, Aron AR, Dowson J, Sahakian BJ, Cognitive enhancing effects of modafinil in healthy volunteers, in Psychopharmacology (Berl.), vol. 165, n. 3, 2003, pp. 260–9, DOI:10.1007/s00213-002-1250-8, PMID 12417966.
Randall DC, Viswanath A, Bharania P, Elsabagh SM, Hartley DE, Shneerson JM, File SE, Does modafinil enhance cognitive performance in young volunteers who are not sleep-deprived?, in J Clin Psychopharmacol, vol. 25, n. 2, 2005, pp. 175–9, DOI:10.1097/01.jcp.0000155816.21467.25, PMID 15738750.
Müller U, Steffenhagen N, Regenthal R, Bublak P, Effects of modafinil on working memory processes in humans, in Psychopharmacology (Berl.), vol. 177, n. 1-2, 2004, pp. 161–9, DOI:10.1007/s00213-004-1926-3, PMID 15221200.
Hart CL, Haney M, Vosburg SK, Comer SD, Gunderson E, Foltin RW, Modafinil attenuates disruptions in cognitive performance during simulated night-shift work, in Neuropsychopharmacology, vol. 31, n. 7, luglio 2006, pp. 1526–36, DOI:10.1038/sj.npp.1300991, PMID 16395298.
Dackis CA, Kampman KM, Lynch KG, Pettinati HM, O'Brien CP, A double-blind, placebo-controlled trial of modafinil for cocaine dependence, in Neuropsychopharmacology, vol. 30, n. 1, 2005, pp. 205–11, DOI:10.1038/sj.npp.1300600, PMID 15525998.
Umanoff DF, Trial of modafinil for cocaine dependence, in Neuropsychopharmacology, vol. 30, n. 12, 2005, pp. 2298; author reply 2299–300, DOI:10.1038/sj.npp.1300866, PMID 16294193.
Dackis CA, Kampman KM, Lynch KG, Pettinati HM, O'Brien CP, Reply: Do Self-Reports Reliably Assess Abstinence in Cocaine-Dependent Patients?, in Neuropsychopharmacology, vol. 30, n. 12, 2005, pp. 2299–300, DOI:10.1038/sj.npp.1300867.
David Henderson, Modafinil-Associated Weight Loss in a Clozapine-Treated Schizoaffective Disorder Patient, in Annals of Clinical Psychiatry;, vol. 17, n. 2, aprile–giugno 2005, pp. 95–97, DOI:10.1080/10401230590932407.
Vaishnavi S, Gadde K, Alamy S, Zhang W, Connor K, Davidson JR, Modafinil for atypical depression: effects of open-label and double-blind discontinuation treatment, in J Clin Psychopharmacol, vol. 26, n. 4, agosto 2006, pp. 373–8, DOI:10.1097/01.jcp.0000227700.263.75.39, PMID 16855454.
Makris AP, Rush CR, Frederich RC, Kelly TH, Wake-promoting agents with different mechanisms of action: comparison of effects of modafinil and amphetamine on food intake and cardiovascular activity, in Appetite, vol. 42, n. 2, aprile 2004, pp. 185–95, DOI:10.1016/j.appet.2003.11.003, PMID 15010183.
Bonaventure P, Letavic M, Dugovic C, et al, Histamine H3 receptor antagonists: from target identification to drug leads, in Biochem. Pharmacol., vol. 73, n. 8, aprile 2007, pp. 1084–96, DOI:10.1016/j.bcp.2006.10.031, PMID 17129577.

provigil.com

"Provigil (Modafinil) Site." 12/24/1998 Provigil - Prescription Medicine Used to Improve Wakefulness, su provigil.com..

psychiatrist.com

article.psychiatrist.com

Rabkin JG, McElhiney MC, Rabkin R, Ferrando SJ, Modafinil treatment for fatigue in HIV+ patients: a pilot study, in J Clin Psychiatry, vol. 65, n. 12, dicembre 2004, pp. 1688–95, PMID 15641875.

psychiatryonline.org

psy.psychiatryonline.org

Glen L. Xiong, M.D., Eric J. Christopher, M.D., and Jason Goebel, M.D., Modafinil as an Alternative to Methylphenidate as Augmentation for Depression Treatment, in Psychosomatics, vol. 46, Academy of Psychosomatic Physician, 2005, pp. 578–579, DOI:10.1176/appi.psy.46.6.578, PMID 16288139.
«Case report: Modafinil 200 mg daily replacing Methylphenidate 5 mg b.i.d in 78 year old cardiac patient»

unibo.it

acnpsearch.unibo.it

(EN) P. Jenner, B.-Y. Zeng, L.A. Smith, R.K.B. Pearce, B. Tel, L. Chancharme e G. Moachon, Antiparkinsonian and neuroprotective effects of modafinil in the mptp-treated common marmoset (abstract), vol. 133, Springer-Verlag, luglio 2000, pp. 178-188, DOI:10.1007/s002210000370, ISSN Print ISSN 0014-4819; Online ISSN 1432-1106 (WC · ACNP). URL consultato il 17 ottobre 2022 (archiviato dall'url originale l'11 gennaio 2013).

web.archive.org

Erman MK, Rosenberg R, For The U S Modafinil Shift Work Sleep Disorder Study Group. "Modafinil for excessive sleepiness associated with chronic shift work sleep disorder: effects on patient functioning and health-related quality of life." Primary Care Companion to the Journal of Clinical Psychiatry 2007;9(3):188-94. Full Text (PDF) (archiviato dall'url originale il 15 luglio 2011).
van Vliet SA, Vanwersch RA, Jongsma MJ, van der Gugten J, Olivier B, Philippens IH, Neuroprotective effects of modafinil in a marmoset Parkinson model: behavioral and neurochemical aspects, in Behav Pharmacol, vol. 17, n. 5-6, settembre 2006, pp. 453–62, PMID 16940766. URL consultato il 1º ottobre 2008 (archiviato dall'url originale il 26 febbraio 2012).
News Release (Cephalon). "Cephalon, Inc. Plans to Acquire France's Group Lafon." WEST CHESTER, Pa., Dec 3, 2001 (PR Newswire) Link (archiviato dall'url originale il 10 febbraio 2007).
Efficacy and Safety of Modafinil Film-Coated Tablets in Children and Adolescents (PDF) (archiviato dall'url originale il 10 febbraio 2012).
11613_Provigil_PI_4pgr_lo4.indd (PDF) (archiviato dall'url originale il 1º maggio 2015).
"Doctors are finding it harder to deny 'Chemobrain'" (archiviato dall'url originale il 12 ottobre 2007)., The Virginian-Pilot, 2 ottobre 2007.
Modafinil Relieves Cognitive Chemotherapy Side Effects (archiviato dall'url originale l'11 ottobre 2008). Psychiatric News, Stephanie Whyche, August 3, 2007 Volume 42 Number 15, page 31

worldcat.org

(EN) P. Jenner, B.-Y. Zeng, L.A. Smith, R.K.B. Pearce, B. Tel, L. Chancharme e G. Moachon, Antiparkinsonian and neuroprotective effects of modafinil in the mptp-treated common marmoset (abstract), vol. 133, Springer-Verlag, luglio 2000, pp. 178-188, DOI:10.1007/s002210000370, ISSN Print ISSN 0014-4819; Online ISSN 1432-1106 (WC · ACNP). URL consultato il 17 ottobre 2022 (archiviato dall'url originale l'11 gennaio 2013).